Database

Startups

Main Industry
Health Care
Main Product/Service
Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient.
Founded Year
2020
Unified Business No.
83304134
Status
Active
Number of Employees
23
Total Paid-in Capital
200,000,000 (NT$)
Location of Company
Taiwan , New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Introduction
UWELL BioPharma, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotheraputics designed to harness the power of a patient’s own immune system to target and eradicate cancer cells. We do th



More2 ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

GenomeFrontier Therapeutics TW Co., Ltd.

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and
:::